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Background: Cardiovascular risk is increased in the early stages of chronic kidney disease (CKD) and also found to be
ongoing in renal transplant (Rtx) patients. As a sign of atherosclerosis, increased carotid intima-media thickness (CIMT)
has been widely accepted as a strong predictor of cardiovascular disease (CVD) and mortality in CKD patients. A novel
markers, soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and neutrophil-to-lymphocyte ratio (NLR)
were introduced as potential markers in inflammatory disorders including CKD. The role of Rtx in terms of atherogenesis
is still unclear. We aimed to investigate the relationship between sTWEAK, NLR and CIMT in Rtx patients without overt
CVD and to compare these results with those obtained from healthy subjects.
Methods: Cross-sectional analysis in which CIMT measurements, NLR and serum TWEAK levels were assessed in 70 Rtx
patients (29 females; mean age, 40.6 ± 12.4 years) and 25 healthy subjects (13 females, mean age; 37.4±8.8 years).
Results: sTWEAK levels were significantly decreased (p=0.01) and hs-CRP, NLR and CIMT levels of Rtx patients
were significantly increased compared to healthy subjects (p<0.0001, p=0.001, p<0.0001, respectively). sTWEAK
was also found to be decreased when eGFR was decreased (p=0.04 between all groups). CIMT was positively
correlated with sTWEAK and NLR in Rtx patients (r=0.81, p<0.0001 and r=0.33, p=0.006, respectively). sTWEAK was
also positively correlated with NLR (r=0.37, p=0.002). In the multivariate analysis only sTWEAK was found to be an
independent variable of increased CIMT.
Conclusion: sTWEAK might have a role in the pathogenesis of ongoing atherosclerosis in Rtx patients.
Keywords: sTWEAK, Neutrophil-to-lymphocyte ratio, Carotid intima-media thickness, Renal transplantationBackground
Despite improvements in diagnostic tools and thera-
peutic approaches, premature death related to cardiovas-
cular disease (CVD) remains the most common cause of
death in patients with chronic kidney disease (CKD) [1].
Cardiovascular risk is increased even in the early stages
of CKD and this heightened risk is also found after renal
transplantation (Rtx) [2,3]. Besides traditional risk fac-
tors including hypertension, diabetes, dyslipidemia, ad-
vanced age and left ventricular hypertrophy (LVH),
novel risk factors such as endothelial dysfunction (ED),
vascular calcifications, oxidative stress, and inflammation* Correspondence: mdkt2010@yahoo.com
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reproduction in any medium, provided the orare highly prevalent and seem to play a more important
role in renal patients compared to healthy subjects [4-7].
Several studies suggested that persistent systemic in-
flammation could be the main factor responsible for
the increased risk in ESRD patients, regardless of the
renal replacement therapy [8]. To prove this hypothesis,
researchers analyzed a large panel of biomarkers to fully
characterize the relation between inflammation and CVD,
including C-reactive protein, interleukin (IL)-1β, IL-6,
tumor necrosis factor-α (TNF- α) [8,9], as well as several
interesting new biomarkers.
Neutrophil-to-lymphocyte ratio (NLR) is a potential
marker for inflammation in cardiac and non-cardiac disor-
ders [10-12] that was also shown to be a predictor of long
term mortality in patients who underwent percutaneous
coronary intervention [13]. We recently demonstrated thatal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Recently, a novel marker - the soluble tumor necrosis
factor-like weak inducer of apoptosis (sTWEAK, TNFSF12)
was introduced as a tumor necrosis factor (TNF) related
cytokine in various inflammatory and non-inflammatory
disorders [15]. To date, a transmembrane protein, fibro-
blast growth factor-inducible 14 (Fn14) and a scavenger re-
ceptor, CD163 were discovered as receptors of sTWEAK
[16,17]. Binding of sTWEAK to Fn14 mediates multiple ef-
fects, including cellular growth, proliferation, migration,
differentiation, apoptosis, angiogenesis, fibrogenesis and in-
flammation [18]. A soluble form of CD163 was also discov-
ered and introduced as a risk factor for long term mortality
in patients with peripheral artery disease [19].
Since the association between TWEAK and subclinical
atherosclerosis was demonstrated in general and CKD
populations [20,21], we aimed to investigate the relation-
ship between sTWEAK, NLR and carotid IMT (CIMT)
in Rtx patients without overt CVD and to compare these
results with those obtained from healthy subjects.
Methods
The study protocol was approved by the Medical Ethics
Committee of Selcuk University (Meram School of
Medicine, Konya, Turkey). Written informed consent was
obtained from all subjects included in the study.
This was a cross-sectional study involving 70 Rtx pa-
tients (29 females, 41 males; mean age, 40.6 ± 12.4 years)
followed for at least 6 months in the transplantation unit
of the Necmettin Erbakan University and 25 healthy
subjects (13 females; mean age, 37.4 ± 8.8 years) between
January and November 2011.
Patients aged 18–70 years willing to participate in the
assessment of CIMT by carotid duplex ultrasonography
were screened. A review of medical records (including
information on age; sex; weight; medications; primary
disease of ESRD) was undertaken. Exclusion criteria were:
(i) angina pectoris and/or documented coronary artery
disease, (ii) congestive heart failure; (iii) active infec-
tion; (iv) autoimmune disease; (v) severe secondary
hyperparathyroidism (patients with iPTH > 500 pg/mL);
(vi) nephrotic-range proteinuria and vii) patients with HIV,
HBV and HCV history. Eighty-six RTx patients were
screened and 16 patients were excluded from the study. Of
the 16 excluded patients - 7 had documented coronary ar-
tery disease, 4 congestive heart failure (New York Heart
Association (NYHA) class III–IV); 2 active infection; 2
secondary hyperparathyroidism; and 1 patient had auto-
immune disease. None of the patients included in the
study had nephrotic-range proteinuria and arrhythmia
based on electrocardiography (ECG).
Twenty-five age and sex-matched normotensive healthy
individuals (13 females, mean age; 37.4 ± 8.8 years)
referred from outpatient clinics of the Internal MedicineDepartment of Necmettin Erbakan University were en-
rolled as control subjects. They were subjected to the
same inclusion and exclusion criteria as the trans-
planted patients.
Blood pressure was measured in the upright sitting
position after ≥5 min of rest using an Erka sphygmo-
manometer (PMS Instruments Limited, Berkshire, UK)
with an appropriate cuff size. Two readings were recorded
for each individual. The mean value of the two readings
was defined as the blood pressure. Patients with SBP and
DBP ≥140 mmHg and ≥90 mmHg respectively were as-
sumed to be hypertensive. Forty-two patients were taking
anti-hypertensive drugs (all patients were on verapamil).
Eleven patients were taking an oral calcium-vitamin D
combination, and 9 patients were on active vitamin D.
Ten patients (14.3%) were on intensive insulin and 16
(22.9%) were on oral anti-diabetic medication. All 70
Rtx patients, were on prednisolone and mycophenolate
mofetil (MMF), 60 (85.7%) were on tacrolimus, 4 (5.7%)
were on cyclosporine-A (Cyc-A), 2 were on sirolimus
(2.9%) and 4 (5.7%) were on everolimus therapy. The
donor source was living-related in 32 (45.7%), living-
unrelated in 4 (5.7%) and deceased-donor in 34 (48.6%) pa-
tients. None of the patients had transplant nephrectomy.
Biochemical analyses
Venous blood samples were drawn after an overnight
fast and stored at -80°C for biochemical analyses. Serum
creatinine, urea, aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), calcium, albumin, uric acid,
total cholesterol (TC), high density lipoprotein choles-
terol (HDL-C), triglyceride (TG) and phosphorus (P)
were determined using a Synchron LX20 system (Beckman
Coulter, USA) with original Beckman reagents. HDL-C
levels were determined by a direct enzymatic method,
without precipitation. LDL-C levels were calculated using
the Friedewald formula [22]. Serum hs-CRP levels were
measured with a high sensitive immunoturbidimetric assay
(Diasis Diagnostic System) using an automated clinical
chemistry analyzer. Normal range reference interval of hs-
CRP for adults was accepted as <10 mg/L.
STWEAK measurements
Serum TWEAK levels were measured, in both patients
and healthy controls, by a commercially available, kit
based on enzyme-linked immunosorbent assay (eBiosience,
Human TWEAK Instant Elisa, Cat no: BMS2006INST).
The results were expressed as pg/mL. The calculated over-
all intra-assay coefficient of variation (CV) was 7.9%.
Definition of NLR
Complete blood counts with automated differential counts,
which included total white blood cells, neutrophils
and lymphocytes, obtained at the time of admission.
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and lymphocytes, obtained from the same automated
blood sample.
Glomerular filtration rate (GFR) assesment
GFR was calculated according to the simplified version
of the Modification of Diet in Renal Disease (MDRD)
Study prediction equation formula, GFR=186 * Creatin-
ine-1.154 * Age-0.203 * 1.212 (if African-American)* 0.742
(if female), as defined by Levey [23].
Carotid intima-media thickness measurements
The carotid intima media thickness recordings were
performed by a single investigator who was blinded for
patient’ charateristics. The carotid arteries were evalu-
ated with the Vivid 7 echocardiography device (General
Electrics, Horten, Norway) by using a 10-MHz linear
probe. The acquired images were recorded for playback
analysis and were later measured off-line. The common
carotid artery, the carotid bulb, and internal and external
carotid arteries were visualized on both sides. The IMT
of the carotid arteries were measured in the distal com-
mon carotid artery at a level 15 to 20 mm proximal to
the carotid bulb. The two bright echogenic lines in the
arterial wall were identified as the intima and the media.
Three measurements were made for each side of the
body; separate means were calculated and recorded as
the right and left IMT. The intraobserver coefficient of
variation for carotid IMT was 2.0%.
Abnormal CIMT was defined as CIMT ≥0.82 mm to
characterize atherosclerosis [24].
Statistical analyses
Statistical analyses were carried out using the Statistical
Package for Social Sciences for Windows version 15.0
(SPSS, Chicago, IL, USA). Data are expressed as the
mean ± SD, with a significance level of P < 0.05. The
normal distribution of all variables was tested using the
Kolmogorov-Smirnov Test. Dichotomous variables were
compared using the chi-square test. Statistical differences
between parametric data of two groups were analyzed
using the Student’s t-test. The Mann–Whitney U test was
used to determine differences between non-parametric
data. The non-parametric Spearman coefficient of correl-
ation was used to assess correlations between variables
without normal distribution. The Rtx patients were di-
vided into tertiles of eGFR. Differences among tertiles
were analyzed by one-way ANOVA.
Multivariate linear regression analyses were undertaken
to determine independent associations among CIMT and
other variables. Age, serum phosphorus, LDL-cholesterol,
hs-CRP, NLR, and sTWEAK were entered into the regres-
sion model as independent variables, and CIMT was en-
tered as a dependent variable. The backward eliminationmethod was preferred in the stepwise regression analysis
and p>0.1 used as a criterion for elimination in this model.
At the end of the fifth step, only sTWEAK was remained
statistically significant in the model. p< 0.05 was consid-
ered significant for all tests.
Results
Patients’ baseline characteristics
The baseline characteristics of the 70 Rtx patients and
25 healthy subjects are depicted in Table 1. The etiology
of renal disease in Rtx patients was chronic glomerulo-
nephritis (n=6, 8.6%), diabetic nephropathy (n=6, 8.6%),
hypertensive nephropathy (n=13, 18.6%), polycystic kid-
ney disease (n=2, 3.3%), tubulointerstitial nephritis (n=4,
5.7%), amyloidosis (1, 1.4%) and unknown etiology (n=38,
53.8%). Of 70 Rtx patients, 42 (60%) had post-transplant
hypertension, 47 (67.1%) had post-transplant dyslipidemia,
and 20 (28.6%) had new-onset diabetes after transplant-
ation (NODAT). There were no differences in age, gen-
der, biochemical parameters including serum LDL and
HDL cholesterol, AST, ALT and phosphorus between
Rtx patients and healthy subjects. Spot urine protein
to creatinine ratio (PCR) values of healthy controls
and Rtx patients were 0.01±0.1 and 0.3±0.2, respect-
ively (p<0.0001). Serum glucose, urea, creatinine, uric
acid, triglyceride and calcium were significantly higher
in Rtx patients compared to controls (Table 1). Esti-
mated GFR measurements were also found to be sig-
nificantly lower in Rtx patients than healthy subjects
(61.7±22.2 vs 119.2±32.9, respectively, p<0.0001).
STWEAK, NLR, hs-CRP and carotid intima media thickness
measurements
Results of inflammation and atherosclerosis markers in-
cluding sTWEAK, hs-CRP, NLR and CIMT are shown in
Table 2 with univariate correlates of CIMT and sTWEAK
in Rtx patients. sTWEAK levels were significantly de-
creased (p=0.01) and hs-CRP levels were significantly in-
creased (p<0.0001) in Rtx patients compared to healthy
subjects. Neutrophil count and NLR were also signifi-
cantly higher in Rtx patients compared to healthy con-
trols (p<0.0001, p=0.001, respectively). The mean CIMT
of Rtx patients and healthy subjects were 0.72±0.28mm
and 0.41±0.07mm, respectively (p<0.0001).
In order to analyze the values of sTWEAK, NLR,
hs-CRP, and CIMT according to renal function of Rtx
patients, we defined a high eGFR group (group 1)
with levels above the 66th percentile (upper tertile)
and a low eGFR group (group 3) with levels below
the 33th percentile (lower tertile) (Table 3). NLR and
CIMT were highest and sTWEAK was lowest in eGFR
group 3 (Table 3). Furthermore, sTWEAK are signifi-
cantly decreasing with decreasing levels / tertile of eGFR
(p=0.04 between all groups). There was also significant
Table 1 The baseline characteristics, clinic and laboratory features of the healthy subjects and renal transplant patients





Age (years) 34 (29–43) 38 (31–47) 0.17
Female 13 29 0.48
BMI (kg/m2) 27 (24–29) 24.8 (21.4-28.4) 0.02
SBP (mmHg) 115 (110–120) 122 (110–137) <0.0001
DBP (mmHg) 75 (60–80) 80 (70–90) 0.001
Glucose (mg/dL) 92 (86–105) 92 (86–104) 0.04
Urea(mg/dL) 25 (19–34) 32 (24–39) 0.002
Creatinine (mg/dL) 0.7 (0.6-0.8) 1.1 (0.8-1.4) <0.0001
Albumin (g/dL) 4.4 (4.3-4.5) 4.3 (4.1-4.5) 0.02
Uric acid (mg/dL) 3.7 (3.5-4.6) 5.5 (3.9-7.0) <0.0001
AST(IU/L) 21 (17–22) 21 (17–26) 0.25
ALT(IU/L) 18 (15–20) 19 (15–25) 0.18
LDL Cholesterol (mg/dL) 125 (105–137) 118 (92–134) 0.38
HDL Cholesterol (mg/dL) 46 (38–50) 46 (38–53) 0.69
Triglyceride (mg/dL) 64 (88–147) 144 (101–181) 0.001
Calcium (mg/dL) 8.5 (8.5-9.4) 9.5 (9.1-9.9) 0.0001
Phosphorus (mg/dL) 3.0 (2.7-3.3) 3.0 (2.7-3.6) 0.68
eGFR (ml/min) 107 (91–144) 71 (53–90) <0.0001
Spot urine 0.08 (0.01-0.2) 0.2 (0.05-0.34) <0.0001
protein/creatinine
ratio (g/mg)
Hemoglobin (mg/dL) 13.5 (13.3-14.3) 14 (12.6-14.7) 0.70
Neutrophil (mm3) 3100 (2520–3515) 4260 (3287–5937) <0.0001
Lymphocyte (mm3) 2190 (1690–2583) 2100 (1582–2710) 0.29
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST aspartate aminotransferase, LDL low-density
lipoprotein, HDL high-density lipoprotein, eGFR estimated glomerular filtration rate.
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and eGFR group 2 and group 3 patients (p=0.02 and
p=0.03, respectively).
Predictors of CIMT in Rtx patients
To investigate the relationship between atherosclerosis
and inflammation, we performed a univariate correlation
analysis. CIMT was positively correlated with sTWEAKTable 2 sTWEAK, hs-CRP, NLR and CIMT values of the healthy




hs-CRP (mg/L)* 3,3 (2.25-5.8) 8.9 (4.97-14)
sTWEAK (pg/mL)* 457 (320.5-537.8) 388.9 (324.5-426
NLR 1.16 (0.97-1.5) 2.18 (1.4-2.8)
CIMT (mm) 0.4 (0.4-0.5) 0.5 (0.4-0.9)
sTWEAK soluble TNF-like weak inducer of apoptosis, NLR neutrophil-to-lymphocyte
protein, IQR interquartile range, * represents the variables in median (IQR).
a Spearman rank univariate analysis for sTWEAK in renal transplant patients.
b Spearman rank univariate analysis for CIMT in renal transplant patients.and NLR in Rtx patients (r=0.81, p<0.0001 and r=0.33,
p=0.006, respectively). Serum sTWEAK was also posi-
tively correlated with NLR (r=0.37, p=0.002).
We also checked the relation between serum uric acid
and inflammatory markers. There were no relationship
between serum uric acid and inflammatory markers in-
cluding hs-CRP and NLR (r=0.01, p=0.89 and r=0.05,
p=0.66, respectively).subjects and renal transplant patients
t patients
IQR)
P ρ (Ρ)a ρ (Ρ)b
<0.0001 0,15 (p=0.25) 0.09 (p=0.46)
.9) 0.01 - 0.81 (p<0.0001)
0.001 0.37 (p=0.002) 0.33 (p=0.006)
<0.0001 0.81 (p<0.0001) -
ratio, CIMT carotid intima media thickness, hs-CRP high sensitive C-reactive
Table 3 sTWEAK, NLR, CIMT results according to eGFR groups of renal transplant patients and healthy subjects
Parameters Healthy subjects (n=25)
Median (IQR)
eGFR group 1 (n=23)
Median (IQR)
eGFR group 2 (n=24)
Median (IQR)
eGFR group 3 (n=23)
Median (IQR)
p*
MDRD (mL/min) 107 (52.7) 83 (13.56) 63 (8.7) 42 (22) <0.0001
hs-CRP (mg/L) 3.3 (2.25-5.8) 8.7 (5.6-12.6) 9.45 (4.92-14) 9.0 (3.3-18) <0.0001
NLR 1.16 (0.54) 2.25 (1) 2.16 (1.5) 2.58 (2.5) 0.005
CIMT (mm) 0.4 (0.1) 0.7 (0.4) 0.6 (0.4) 0.7 (0.5) <0.001
sTWEAK (pg/mL) 457 (320.5-537.8) 399.5 (329–439) 382.9 (308.6-421.5) 361.2 (323.4-426.5) 0.04
sTWEAK soluble TNF-like weak inducer of apoptosis, NLR neutrophil-to-lymphocyte ratio, CIMT carotid intima-media thickness, MDRD modification of diet in renal
disease, hs-CRP high sensitive C-reactive protein, IQR interquartile range, eGFR estimated glomerular filtration rate, *p value between all groups.
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to be an independent variable of increased CIMT. Re-
gression results are shown in Table 4.
Discussion
The major findings of the present study were as follows;
i) sTWEAK levels were significantly decreased and CIMT,
NLR and hs-CRP were significantly increased in Rtx pa-
tients compared to healthy subjects, ii) sTWEAK was posi-
tively correlated with CIMT and NLR but not with hs-CRP
in Rtx patients, iii) sTWEAK was found to be an independ-
ent predictor of increased CIMT in Rtx patients.
In recent years, sTWEAK was discovered as a multi-
functional cytokine that was related to the TNF super
family. Description of TWEAK in kidney was reported
for the first time by Justo et al. [25] in a mouse model of
folate-induced acute kidney injury. In the following years,Table 4 The stepwise regression analysis to determine
the independent predictors of carotid-intima media
thickness in renal transplant patients
Parameters Standardized Beta‡ P value 95% CI
Step 1
Age (years) 0.17 0.18 −0.003-0.016
Phosphorus (mg/dL) −0.03 0.78 −0.179-0.135
LDL (mg/dL) −0.11 0.37 −0.006-0.002
hs-CRP (mg/L) 0.13 0.30 −0.007-0.023
NLR 0.03 0.84 −0.089-0.109




TWEAK (pg/mL) 0.42 <0.001 0.001-0.004
adjusted r2=0.20
*p<0.0001
*It was define to model statistic for each step. CI Confidence interval, LDL low
density lipoprotein, hs-CRP high sensitive C-reactive protein, NLR neutrophil-
to-lymphocyte ratio, TWEAK tumor necrosis factor-like weak inducer
of apoptosis.
‡ Standardized Beta means standardized regression coefficients of
the variables.Yilmaz et al. [26] demonstrated that a decline in eGFR was
accompanied by a gradual reduction in sTWEAK in CKD
patients. The same group also showed that endothelial dys-
function and decreased sTWEAK were independently as-
sociated with cardiovascular outcomes in predialytic CKD
patients [21]. In addition, treatment of type 1 hypertensive
diabetic CKD with amlodipin and/or valsartan improves
endothelial dysfunction and normalizes sTWEAK [27].
During the preparation of the present manuscript, Gungor
et al. [28] described a possible role for sTWEAK in the
pathogenesis of atherogenesis in the RTx population.
In our cohort, Rtx patients had lower sTWEAK levels
compared to healthy subjects. However, median values
of sTWEAK levels of our Rtx patient were higher com-
pared to CKD patients in the cohorts of Yilmaz et al.
[21] and Carrero et al. [29] (388.97 pg/mL vs. 245.5 pg/mL
and 208 pg/mL, respectively). We also investigated the re-
lation between sTWEAK and kidney function in Rtx pa-
tients. After the classification of Rtx patients according to
their eGFR, we found that sTWEAK levels were signifi-
cantly decreased when eGFR values were decreased. These
findings are in accord with those obtained by Yilmaz et al.
[26]. Therefore, we hypothesized that the decrease of
sTWEAK among eGFR groups in Rtx patients might be as-
sociated with ongoing inflammation in this population.
Inflammation seen after Rtx has a complex etiology,
including a role for innate and acquired immunity. Mac-
rophages and neutrophils play an important role in the
pathogenesis of inflammation and acute and chronic
allograft rejection [30]. However, ongoing inflammation
in Rtx patients is much less intense compared to CKD
and ESRD patients. Neutrophil-to-lymphocyte ratio was
introduced as a potential marker to determine inflam-
mation in cardiac and non-cardiac disorders [10-12]. In
a previous study, we demonstrated that NLR was posi-
tively correlated with TNF- α in ESRD patients [14]. In
the present study, we found that both hs-CRP and NLR
were significantly increased in Rtx patients suggesting
that these patients had infra-clinic, smoldering inflam-
mation. We also showed that NLR was positively cor-
related with sTWEAK in this population. This finding
might represent the link between inflammation and
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we illustrated this potential pathophysiological rela-
tionship in Figure 1.
Recently, Hornum et al. investigated the effect of Rtx
on arterial function and they showed a significant im-
provement in endothelial function, mean arterial pres-
sure and plasma vWF levels but not in plasma CRP and
albumin levels [31]. Seyahi et al. also demonstrated that
renal transplantation did not reverse or halt the progres-
sion of coronary artery calcification [32]. Our results are
in accord with these studies - Rtx patients had higher
CIMT compared to healthy subjects. Moreover, sTWEAK
and NLR were found to be significantly and positively cor-
related with CIMT. Since sTWEAK is also related to eGFR,
we hypothesize that decreased allograft function is associ-
ated with inflammation and atherosclerosis in a vicious
circle. Therefore, sTWEAK is most probably a pathogenic
cytokine rather than only a biomarker in Rtx patients.
The role of TWEAK in the renal tubulointerstitial in-
flammation was highlighted by Ortiz et al. [33] as an
activator of nuclear factor kappa β (NFkβ), which has
effects on transcription of inflammatory cytokines in-
cluding MCP-1, RANTES, and IL-6 [33]. Tacrolimus,
widely used as an immunosuppressive agent in Rtx pa-
tients, has been shown to down-regulate NFkβ pathway
and induce apoptosis of both activated T cells and mac-
rophages, in IL-10 knockout mice [34]. Recently, Du
et al. [35] showed the importance of suppression of NFkβ
by cyclosporin A and tacrolimus in renal tubular cells. In
our study, out of 70 Rtx patients, 60 were receivingFigure 1 The relationship between sTWEAK and inflammation in renatacrolimus as a main immunosuppressive therapy. Des-
pite the absence of any correlation between tacrolimus
usage and sTWEAK it is plausible to suggest that de-
creased sTWEAK levels might be a compensatory response
to the inhibitory effects of tacrolimus on the NFkB path-
way (Figure 1).
Our study had two main limitations. First, this was a
cross-sectional analysis of Rtx patients focusing on CIMT
and sTWEAK. Second, the sample size was relatively
small. This was not a prospective controlled study and
therefore, we cannot draw cause-and-effect relationships
from our findings.
None of our renal transplant patient died after they
enrolled in this study. Hence, we could not analyze the
relation between inflammation markers and mortality.
However, a prospective study looking at the significance
of these markers in mortality should be done.
Conclusions
sTWEAK might have a role in the pathogenesis of on-
going atherosclerosis in Rtx patients. Rtx may not com-
pletely reverse non-traditional risk factors including
inflammation and atherosclerosis. When considered to-
gether, ongoing inflammation and interactions between
drugs and macrophages might explain why CKD and
ESRD patients had lower sTWEAK levels than Rtx pa-
tients. Renal transplant patients should be assessed to
their inflammatory and uremic status individually. There
are many missing pieces in the puzzle and nothing is yet
known about the clinical implications of sTWEAK in Rtxl transplant patients.
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mental studies investigating the exact roles of sTWEAK in
the pathogenesis of atherosclerosis in renal transplantation
patients are needed.
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